Wellness & Lifestyle

Scoop is an AI platform designed to accelerate drug trials through efficient and accurate regulatory submissions. It specializes in AI-native drafting and continuous maintenance for pre-clinical regulatory documents, converting study and manufacturing data into dynamic, accurate regulatory documents. The platform continuously reconciles updates, ensuring filings remain synchronized with the latest scientific advancements. Key features include ingesting scientific reports and CMC packages, generating submission-ready narratives with traceability, detecting conflicting values and outdated language, and maintaining documents as new studies or manufacturing changes occur. Scoop is built for ongoing regulatory maintenance, offering full traceability from every sentence to its source document and automatic inconsistency detection across modules.

Ada Health offers an AI-powered platform for symptom assessment, helping individuals manage their health and make informed decisions. The tool provides a medical library with easy-to-understand information on conditions and symptoms, created by doctors and grounded in research. For partners, Ada Health offers enterprise solutions to improve health and care, including care utilization, patient finding, and research. It serves as an early digital touchpoint in the patient journey, helping health systems route patients to appropriate care and enabling pharma companies to identify patients before diagnosis. Clinical evidence suggests Ada assessments can increase appropriate care decisions and reduce emergency department visits.

Century Health leverages AI to accelerate medical breakthroughs by utilizing real-world evidence. The platform builds disease-specific registries from Electronic Health Record (EHR) data across U.S. specialty practices, capturing clinical depth and patient diversity for research. Its proprietary AI abstraction engine, CHARM, extracts clinical variables from structured and unstructured EHR data with 97% accuracy and full traceability. This enables providers to gain deeper insights into patient populations and contribute to research, while life sciences companies can access fit-for-purpose real-world datasets for clinical insight, market access, and outcomes analysis. The tool supports a collaborative model for evidence generation, prioritizing patient privacy.

Cellarity is an innovative AI-driven drug discovery platform that redefines how medicines are developed by focusing on dynamic cell states rather than single molecular targets. Its multi-omics AI-powered platform analyzes complex cellular interactions to uncover new biological pathways. This approach enables the regulation of genetic "switches" to restore proper cell function, leading to the creation of "Cell State-Correcting" therapeutics for a range of complex diseases. By moving beyond traditional drug discovery methods limited by human bias, Cellarity aims to provide critical insights into cellular dysfunction and reveal novel biology for disease treatment.

Lunit offers advanced medical AI software designed to revolutionize cancer care by enabling earlier detection and more precise oncology treatments. The platform provides AI-powered solutions for cancer screening, including Lunit INSIGHT MMG (2D) and Lunit INSIGHT DBT (3D) for mammography, and Lunit INSIGHT CXR for chest X-ray analysis. For precision oncology, Lunit SCOPE IO and Lunit SCOPE IHC Suite offer advanced biomarker and companion diagnostic strategies. The software transforms complex clinical data into actionable insights, supporting efficient and confident decisions across the care pathway, from screening to treatment. Lunit partners with radiology and biopharma companies to integrate its AI solutions and accelerate innovation.

TrueMed is an AI-powered platform dedicated to combating counterfeit and diverted medical products. It utilizes proprietary AI and computer vision technology to scan product packaging and identify subtle indicators of counterfeiting or diversion. The system works without requiring any changes to product packaging or the addition of special stickers, inks, or physical security measures. Users can scan products using a mobile device or integrate with backend systems for real-time flagging of suspicious items. TrueMed supports a wide range of medical products, including prescription drugs, over-the-counter products, injectables, vials, and blister packs, and is capable of analyzing images from various digital capture devices. It offers a comprehensive product suite including a Digital Lab for forensic analysis, a Field App for instant verification, and a Consumer App for patient authentication.

NeuralTeks offers an AI-driven multimodal platform designed to revolutionize image analysis in laboratories, particularly for microbiological studies. It leverages advanced AI algorithms for precise identification of various microorganisms from images, enhancing efficiency and reliability. The platform supports diverse inputs, including smartphones, tablets, and microscopes, making microbiological analysis accessible across different lab settings. A key feature is Active Learning, which allows the system to continuously improve accuracy by adapting to user corrections. With a robust API, NeuralTeks seamlessly integrates into existing laboratory systems, ensuring traceability and regulatory compliance. It finds applications across pharmaceutical, food and beverage, research, hospital, environmental monitoring, cosmetics, and agriculture industries.

Upstream Vision is a comprehensive platform dedicated to transforming healthcare through a multi-faceted approach. It focuses on clinical research, developing innovative digital health solutions, and accelerating ventures within the healthcare sector. The tool acts as a digital backbone for clinical trials, patient care, and fostering clinical innovation by integrating biomarker science, advanced AI capabilities, and robust, compliant digital infrastructure. Upstream Vision aims to assist hospitals, life science sponsors, and healthtech innovators in streamlining their processes and accelerating their progress. Its ecosystem includes specialized divisions for managing trials, delivering care, and providing a development platform for new healthcare technologies.

Aigenpulse.com is a domain name currently listed for sale on HugeDomains.com. The domain can be purchased outright for $4,995 or financed through a payment plan of $208.13 per month for 24 months with 0% interest. HugeDomains offers a 30-day money-back guarantee and promises quick delivery of the domain, typically within one to two hours of purchase during business hours. The purchase includes only the domain name, with no additional services like hosting or web design. Buyers can transfer the domain to any registrar after purchase, though payment plan domains are not transferable until fully paid. WhoIs Privacy Protection is available through NameBright.com, the registrar where the domain is pushed after purchase.

AnalysisMode offers AI solutions to unlock the full potential of bioprocessing, primarily through its SimCell platform. SimCell acts as a virtual cell culture lab, allowing users to design and run virtual experiments to predict growth patterns, productivity, and process variability. This accelerates R&D cycles, reduces the need for wet-lab work, and provides data-driven insights for optimizing critical process parameters. Beyond SimCell, AnalysisMode provides tailored AI services covering data assessment, AI-driven Design of Experiments (DoE), digital twin creation for scale-up, and continuous AI feedback loops for real-time monitoring. The platform aims to minimize variability, maximize reliability, and significantly reduce development timelines and costs in bioprocessing.

Nabla Bio is at the forefront of drug development, leveraging generative drug design combined with extensive, patient-relevant testing to transform the discovery process into a precise engineering discipline. The platform integrates data, AI, and both dry and wet-lab systems into a unified engine, enabling the design of medicines with optimized properties such as binding, developability, cellular function, and in-vivo performance. This approach aims to create new medicines that are safer, more precise, and can unlock novel therapeutic targets, ultimately expanding our understanding and treatment of diseases. Nabla Bio partners with leading pharmaceutical companies to maximize the impact of its platform and bring these advanced drug candidates to patients faster.

Synthace offers a unique combination of software and specialized expertise to empower discovery biology teams. The platform enables scientists to design and automate multivariate experiments, streamlining processes like assay development, media optimization, and miniaturized purification. By providing robust software, training, and on-site support from experienced specialists, Synthace helps teams cut down the time to insight and achieve more reliable experimental results. It addresses the challenges of complex, variable-rich experiments in drug discovery, allowing scientists to adopt smarter methods and accelerate project timelines. The tool is designed to integrate with existing lab equipment and foster self-sufficiency within scientific teams over time.

Protein Genesis v2 is an AI service hosted on Hugging Face Spaces, designed to generate protein structures based on user-provided text input. The application is developed by openfree and is intended to provide a platform for researchers and scientists to explore protein design and structural biology through AI. However, the service is currently paused, and users interested in utilizing it are directed to the community tab to request its restart from the author(s). The tool's underlying functionality involves processing textual descriptions to synthesize corresponding protein structures, offering a novel approach to molecular design.

Segmentation Of Teeth In Panoramic X Ray Image Using U Net is an AI-powered tool designed for the automatic segmentation and highlighting of teeth within panoramic X-ray images. Utilizing a U-Net architecture, the application processes uploaded X-ray images to accurately identify and delineate individual teeth. The segmented teeth are then overlaid in red on the original image, providing a clear visual representation. This capability is particularly beneficial for dental professionals, researchers, and students, as it streamlines the analysis of X-ray images, assists in diagnostic processes, and supports dental research by automating a crucial aspect of image interpretation. The tool is accessible via a web interface, allowing users to easily upload images and receive processed results.

ViewMind Inc. is a leading AI-driven platform specializing in the precision measurement of ocular movement alterations, which serve as a window into brain health. Utilizing high sensitivity and specificity, ViewMind's digital assessments contribute significantly to advancing precision drug development and patient care for neurological disorders. The non-invasive system involves an assessment using a head-mounted display (HMD) that tracks eye movements in response to visual stimuli. Patented ocular digital phenotyping, powered by advanced statistical models, analyzes this data to detect minor cognitive alterations or changes to high-level motor function. The platform generates comprehensive reports providing insights into a patient's cognitive condition, accessible to physicians. ViewMind's technology is applicable across various neurocognitive conditions, supporting the diagnostic continuum from early detection to disease progression monitoring and treatment response.

ModAstera is an AI development platform specifically designed for medical teams, streamlining the entire lifecycle of medical AI from raw data to production-ready applications. It addresses common challenges like high costs, long timelines, complex tools for domain experts, and data preparation bottlenecks. The platform provides AI-assisted annotation for better data preparation, tools to train and validate models without rebuilding infrastructure, and features for deploying AI with healthcare-ready documentation and traceability. ModAstera aims to reduce project costs and timelines, making medical AI more accessible and scalable for research groups, healthcare collaborators, and startups.

Optibrium provides an intuitive drug discovery platform designed to accelerate the journey from hit identification to candidate selection. Its core product, StarDrop, is a modular platform for molecular design, optimization, and data analysis, featuring an accessible and intuitive interface. The platform integrates powerful real-time collaboration tools, allowing teams to work together on a single chemistry discovery platform. Optibrium also offers Cerella for AI-guided discovery and BioPharmics for fast, accurate, and robust 3D molecular modeling, including macrocycles. It aims to provide transformative insights and improve decision-making in drug discovery, even with limited data.

Unlearn leverages AI and digital twins to revolutionize clinical development, offering a scientific intelligence layer for pharmaceutical companies. The platform integrates evidence, modeling, and reasoning to empower trial teams with confident decision-making. Key features include TrialPioneer for upstream trial design, which unifies fragmented searches and analyses into an AI-enabled workspace. It also provides Scout for continuous literature and regulatory precedent search, Hindsight for exploring harmonized clinical trial data, and SimLab for building and comparing trial-design scenarios. For monitoring, Unlearn offers Anomaly Detection & Clinical Data Surveillance. Furthermore, it strengthens trial analyses with AI-generated digital twins, which act as external comparators to reduce variability and improve treatment effect detection, leading to smaller sample sizes and faster readouts.

Omniscope is a techbio company at the intersection of AI and immunology, dedicated to advancing the understanding of the immune system. It offers services tailored for biopharma companies, academic researchers, and clinical consortia to decode immune responses, discover biomarkers, and develop next-generation therapies and diagnostics. Omniscope's technology provides an unparalleled view of the adaptive immune system, empowering users to identify rare, disease or treatment-relevant clonotypes and decode immune function. The company also applies its science to sports medicine (osSports) for performance optimization and geroscience (osLifetime) for longevity, helping individuals understand and modify their immune age.

GLOW Below is a physician-formulated skincare solution specifically designed for vaginal health, offering options with bioidentical estrogen or DHEA. This product aims to hydrate, repair, and rejuvenate delicate tissues, providing both immediate relief and long-term benefits. The pH-balanced formula is available without a prescription and can be used alone or in combination for maximum results. It addresses symptoms of Genitourinary Syndrome of Menopause, including dryness, itching, burning, and discomfort, and is formulated with organic, plant-based ingredients, free from parabens and allergens. GLOW Below is made in the USA, FDA registered, Kosher certified, GMP facility, and third-party tested for purity.

SECA Intelligence is the world's first cloud-based AI-enabled investigation and error control software designed exclusively for the pharmaceutical industry. It helps organizations tackle quality issues, glitches, and failures efficiently with intelligent solutions, reducing the cost of quality and ensuring continuous improvement. The platform integrates modules to support quality, compliance, and more effective error control decision-making. Key features include real-time analytics and reporting, a user-friendly interface, flexibility and scalability, compliance-led eSignatures, greater security with role-based accessibility, and a unified database. SECA also offers an audit trail feature to ensure compliance with 21 CFR 11 requirements and provides alerts and notifications for important events.

Nia Therapeutics is pioneering the future of brain-computer interfaces for the treatment of cognitive disorders, specifically focusing on memory loss. Their innovative Smart Neurostimulation System (SNS) is a closed-loop brain-computer interface designed to address verbal memory loss in patients with traumatic brain injury. This AI-driven system aims to transform treatment for millions living with memory loss by generating neural insights that will drive future therapies. Currently in pre-clinical development, the SNS is not yet cleared by the FDA, but early research prototypes have been used in studies approved by Institutional Review Boards, with findings featured in publications like the New York Times and Scientific American.

PrecisionLife leverages world-leading AI and genetic analysis to drive precision medicine beyond oncology, focusing on complex chronic diseases. The platform identifies causal disease biology and stratifies patients with mechanistic biomarkers, enabling the prediction and prevention of chronic conditions. It offers insights for improving health outcomes by predicting lifetime disease risk, determining underlying causes, and personalizing treatment and prevention strategies. For drug development, PrecisionLife discovers novel targets, accelerates clinical trials, and matches patients to appropriate treatments, maximizing success and de-risking programs. Their unique combinatorial analytics generate significant biological signals from less data, providing actionable insights for diagnostics and therapies.

ProtoQSAR is a computational chemistry company specializing in the development and optimization of active compounds across diverse areas like pharmaceuticals, cosmetics, and functional foods. Their ProtoPRED platform utilizes proprietary QSAR (Quantitative Structure-Activity Relationships) models to predict a wide spectrum of industrial and regulatory properties, ensuring compliance with regulations like REACH and ICH. This tool provides a fast, economical, and ethical alternative to animal testing, aligning with the 3Rs principle. ProtoQSAR also offers custom studies, computational toxicology assessments, molecular modeling, and training courses. Their services are designed to help companies efficiently meet regulatory requirements and optimize their registration processes.